Merus (NASDAQ:MRUS) Given a $110.00 Price Target by BMO Capital Markets Analysts

Merus (NASDAQ:MRUS) received a $110.00 price target from equities researchers at BMO Capital Markets in a note issued to investors on Friday, Marketbeat Ratings reports. The firm currently has an “outperform” rating on the biotechnology company’s stock. BMO Capital Markets’ price objective would suggest a potential upside of 99.49% from the stock’s current price.

A number of other research firms also recently issued reports on MRUS. Piper Sandler initiated coverage on Merus in a research report on Thursday, February 13th. They set an “overweight” rating and a $84.00 price target for the company. William Blair reissued an “outperform” rating on shares of Merus in a research report on Monday, April 28th. Guggenheim reissued a “buy” rating and set a $109.00 price target on shares of Merus in a research report on Friday, March 28th. Wells Fargo & Company decreased their target price on Merus from $91.00 to $89.00 and set an “overweight” rating for the company in a research report on Thursday, May 8th. Finally, HC Wainwright reiterated a “buy” rating and issued a $85.00 target price on shares of Merus in a research note on Monday, March 3rd. Fourteen analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $86.00.

Merus Stock Up 32.5%

Shares of NASDAQ:MRUS opened at $55.14 on Friday. The company has a market cap of $3.82 billion, a P/E ratio of -13.96 and a beta of 0.94. Merus has a 52 week low of $33.19 and a 52 week high of $61.28. The business has a fifty day simple moving average of $42.72 and a 200-day simple moving average of $43.41.

Merus (NASDAQ:MRUS) last posted its quarterly earnings results on Wednesday, May 14th. The biotechnology company reported ($1.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.23). Merus had a negative net margin of 680.61% and a negative return on equity of 38.89%. The firm had revenue of $26.49 million for the quarter, compared to analysts’ expectations of $7.82 million. Sell-side analysts expect that Merus will post -3.85 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of MRUS. Avior Wealth Management LLC purchased a new position in Merus in the fourth quarter valued at about $76,000. KBC Group NV boosted its holdings in Merus by 4,583.6% in the fourth quarter. KBC Group NV now owns 57,234 shares of the biotechnology company’s stock valued at $2,407,000 after purchasing an additional 56,012 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its holdings in Merus by 10.7% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 14,517 shares of the biotechnology company’s stock valued at $610,000 after purchasing an additional 1,398 shares during the last quarter. State of New Jersey Common Pension Fund D boosted its holdings in Merus by 29.0% in the fourth quarter. State of New Jersey Common Pension Fund D now owns 48,268 shares of the biotechnology company’s stock valued at $2,030,000 after purchasing an additional 10,842 shares during the last quarter. Finally, TimesSquare Capital Management LLC boosted its holdings in Merus by 21.6% in the fourth quarter. TimesSquare Capital Management LLC now owns 331,195 shares of the biotechnology company’s stock valued at $13,927,000 after purchasing an additional 58,760 shares during the last quarter. Hedge funds and other institutional investors own 96.14% of the company’s stock.

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.